Cambridge Associates Llc Activity Analysis: Q2 2026 Portfolio Shifts

Cambridge Associates Llc's portfolio underwent substantial shifts during the quarter ending June 30, 2026. The firm significantly increased its exposure in specific sectors while strategically adjusting holdings within broad-based index funds.

Prominent Purchases: Sector Focus and Core Enhancements

Cambridge Associates demonstrated a clear focus on sector-specific opportunities during Q2, making substantial purchases that reflect targeted allocation strategies. The firm significantly boosted its position in VUG, investing approximately $46.5 million to increase its weighting from 0.1% to a notable 0.67%. This move suggests confidence in the performance and prospects of small-cap US stocks, particularly within technology sectors.

Furthermore, Cambridge Associates significantly expanded its holdings in IDEV, adding roughly $34.6 million to bring its allocation up from an unknown previous level to 0.5%. This substantial increase points towards a strategic interest in the US Dividend Yield ETF, likely seeking income generation and stability.

The firm also showed strong conviction in BSV, investing around $29.5 million to elevate its position from 0.43% to a higher allocation (the exact percentage isn't provided but the increase was significant). This indicates an increased focus on US Biotech stocks, which are known for high growth potential alongside associated volatility.

Additionally, Cambridge Associates bolstered its fixed income presence through purchases in AGG, adding approximately $129.5 million to increase its allocation from 0.36% (likely the previous level). This suggests a continued search for diversification and yield outside of equities.

Strategic Sales: Reducing Exposure, Maintaining Flexibility

In contrast to their buying activities, Cambridge Associates also made strategic reductions during Q2. The firm significantly decreased its position in ESGV, selling shares worth about $70.4 million and reducing the fund's allocation from an unknown previous level down to 0.19%. This exit could be part of rebalancing efforts or a response to changing market dynamics.

They also sold substantial amounts in other large-cap US equity index funds, including VOO, which saw its position reduced by 0.55% (shares decreased by $1.8 million), and VT experienced a decrease of 4.91% in shares ($263.7 million reduction). These sales, while not drastically altering the overall allocation for these funds (as they remain top positions), signal adjustments within their core US equity holdings.

The sale of VTI shares worth $56.4 million further underscores a measured approach to broad US market exposure, reducing its weighting by 3.25% (shares decreased). Similarly, the reduction in VEA shares by $16.9 million (-1.76%) and a decrease of 0.55% for VOO ($VTI) might be part of tactical shifts or performance-based rebalancing.

Bond Market Adjustments and Other ETF Activity

Cambridge Associates' activity in the fixed income space was also evident, though less pronounced than their equity moves. They sold shares in AGG, reducing its allocation by 34.04% (shares decreased by $269 million). This significant reduction suggests a deliberate decrease in exposure to the broad US bond market index.

Conversely, they purchased shares in SGOV, adding about $24.6 million which increased its allocation from 0.36% (likely previous) to a higher level (though the exact new percentage isn't provided). This indicates interest in short-term government bond ETFs, possibly for tactical yield considerations or cash flow management.

Elsewhere, they maintained holdings like VGSH, which saw an increase of 9.63% (shares increased by $10.7 million), and continued to hold significant positions in funds such as VOO (-0.55%), VT (+4.91%, but this is a change percentage, not necessarily new purchase), VEA (-1.76%), VGIT (+3.42%), and VTIP (+4.32%). The changes in these established holdings reflect ongoing portfolio management rather than brand-new positions.

Overall Portfolio Structure

The total value of Cambridge Associates' portfolio stood at $6.88 billion as of June 30, 2026. Their top five holdings by weight were VOO (27.3%), VT (20.46%), VEA (9.7%), VGIT (5.39%), and VTIP (4.12%). These figures highlight the continued dominance of US equity exposure, particularly broad-based and international index funds.

The portfolio held 53 distinct holdings, with top five weight representing approximately 71.8% of the total value. This indicates a diversified approach despite significant changes in specific positions during the quarter. The presence of both large inflows (significant buys) and large outflows (has_large_sells) confirms an active management style focused on optimizing returns and risk.